Dihexa works by binding to hepatocyte growth factor (HGF) and c-Met receptor complexes, stimulating brain-derived neurotrophic factor (BDNF)-like activity
That is, application of the ASC conversion factor was designed to result in aggregate Medicare expenditures under the revised ASC payment system in CY 2008 being equal to aggregate Medicare expenditures that would have occurred in CY 2008 in the absence of the revised system, taking into consideration the cap on ASC payments in CY 2007, as required under section 1833(i)(2)(E) of the Act (72 FR 42522)
Ciani L, Boyle KA, Dickins E, Sahores M, Anane D, Lopes DM, et al
Background The intent of transitional device pass-through payment, as implemented at 42 CFR 419.66, is to facilitate access for beneficiaries to the advantages of new and truly innovative devices by allowing for adequate payment for these new devices while the necessary cost data is collected to incorporate the costs for these devices into the procedure APC rate (66 FR 55861)
